Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mogrify

Request full access

Transforming the development of life saving cell therapies via the licence of proprietary cell conversions tailored to any therapeutic application

Cambridge, United KingdomFounded 2016Biotech & Life Sciences

About Mogrify

Mogrify operates in the biotechnology sector, focusing on the development of ex vivo cell therapies and pioneering in vivo reprogramming therapies. The company has developed a proprietary platform that leverages transcriptomic and epigenetic data to identify optimal combinations of transcription factors for converting any cell type into another. This technology is aimed at addressing diseases with high unmet clinical needs by enabling scalable and efficient cell conversions. Mogrify serves pharmaceutical companies, research institutions, and healthcare providers, offering solutions that enhance the development and maintenance of cell therapies. The business model is based on licensing its technology, forming strategic partnerships, and executing royalty-bearing deals. Revenue is generated through upfront payments, milestone payments, and royalties from commercialized therapies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
61.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Precision Medicine, Synthetic Biology, Spinout, Biotech and Pharma, AI Drug Discovery, Techbio, Techbio Drug Discovery, Longevity
Technology
Big Data
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Oct 2023 $10M $85M Astellas Venture · Ahren Innovation Capital · Jonathan Milner · Parkwalk Advisors ↗
SERIES AEquity / VC Sep 2021 $0 — Undisclosed —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Mogrify website traffic

Latest recorded traffic for Mogrify is 300 monthly website visits, down 61.5% over the last three months. Mogrify's team declined 21.4% over the past year.

Latest monthly visits300 3-month web change-61.5% 1-year team growth-21.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Mogrify in the Cambridge ecosystem

Live from Dealroom

The Mogrify office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Ahren Innovation Capital
  • 24Haymarket

Series A5 investors entered at this stage

  • University of Bristol Enterprise Fund
  • Parkwalk Advisors
  • Dr Darrin M Disley OBE
  • Jonathan Milner
  • Astellas Venture

Other known investors3 additional known investors

  • Monash University
  • University of Bristol
  • D+V Nachfolge
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Mogrify’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.